$イミューロプレサイズ アンチボディー(IPA.US)$ NEWS Epitope Binning Powered By LENSai TM Technology Can Analyze Over 5,000 Sequences With No Physical Materials Needed, Matches Classical Wet Lab Binning Results VICTORIA, BC / ACCESSWIRE / April 22, 2024 /ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA), an AI-driven biotherapeutic research and technology company, has recently announced an expansion of its already successful LENSai TMPlatform. LENSai, which is run by the company's subsidiary, BioStrand, provides a ...
$イミューロプレサイズ アンチボディー(IPA.US)$ NEWS ImmunoPrecise Antibodies And InterSystems Partner To Leverage AI In Life Sciences, Transforming Patient Care With Accelerated Discovery And Delivery Of Treatments
$イミューロプレサイズ アンチボディー(IPA.US)$NEWS EXCLUSIVE: ImmunoPrecise Antibodies Tells Benzinga 'This Collaboration Integrates the New Vector Search Capability of the InterSystems IRIS Data Platform With IPA's Subsidiary BioStrand's LENS Platform for AI-driven Applications in Healthcare'
$イミューロプレサイズ アンチボディー(IPA.US)$Press Release: IPA Acquires the Carterra LSA(R) Instrument to Enhance Antibody Discovery and Bolster Its AI Developments Dow Jones· 4 mins ago
$イミューロプレサイズ アンチボディー(IPA.US)$Financial Performance: ImmunoPrecise reported a Q3 2024 revenue of $6.2 million, a 20.3% increase year-over-year. Year-to-date revenue reached $18.1 million, showing a 20% rise from fiscal 2023. The company reduced its net loss to $2.9 million or $0.11 per share from the previous year's loss of $4.7 million, or $0.19 per share. Cash balance at the end of Q3 2024 was $6.2 million, compared to $8.3 million in the previous year. R&D expenses were app...
イミューロプレサイズ アンチボディーに関するコメント
NEWS
Epitope Binning Powered By LENSai TM Technology Can Analyze Over 5,000 Sequences With No Physical Materials Needed, Matches Classical Wet Lab Binning Results
VICTORIA, BC / ACCESSWIRE / April 22, 2024 /ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA), an AI-driven biotherapeutic research and technology company, has recently announced an expansion of its already successful LENSai TMPlatform. LENSai, which is run by the company's subsidiary, BioStrand, provides a ...
NEWS
ImmunoPrecise Antibodies And InterSystems Partner To Leverage AI In Life Sciences, Transforming Patient Care With Accelerated Discovery And Delivery Of Treatments
読み込み中...
EXCLUSIVE: ImmunoPrecise Antibodies Tells Benzinga Co's Subsidiary BioStrand And InterSystems Announce A Collaboration For AI-Driven Healthcare Applications
EXCLUSIVE: ImmunoPrecise Antibodies Tells Benzinga 'This Collaboration Integrates the New Vector Search Capability of the InterSystems IRIS Data Platform With IPA's Subsidiary BioStrand's LENS Platform for AI-driven Applications in Healthcare'
Dow Jones· 4 mins ago
ImmunoPrecise reported a Q3 2024 revenue of $6.2 million, a 20.3% increase year-over-year.
Year-to-date revenue reached $18.1 million, showing a 20% rise from fiscal 2023.
The company reduced its net loss to $2.9 million or $0.11 per share from the previous year's loss of $4.7 million, or $0.19 per share.
Cash balance at the end of Q3 2024 was $6.2 million, compared to $8.3 million in the previous year.
R&D expenses were app...
まだコメントはありません